esterase inhibitor protease inhibitor belonging serpin main function inhibition complement system prevent spontaneous activation also major regulator contact acutephase protein circulates blood levels around gl levels rise inflammation irreversibly binds inactivates proteases complex classical pathway complement proteases mbl complexes lectin pathway also inactivated way prevents proteolytic cleavage later complement components mbl although named complement inhibitory activity also inhibits proteases fibrinolytic clotting kinin pathways note important physiological inhibitor plasma kallikrein fxia fxiia largest member among serpin superfamily proteins noted unlike family members structure cterminal serpin domain similar serpins part provides inhibitory activity nterminal domain also times referred nterminal tail essential inhibit proteases domain similarity proteins highly glycosylated bearing n oglycans nterminal domain especially heavily human gene located eleventh chromosome deficiency protein associated hereditary angioedema hereditary angioneurotic edema swelling due leakage fluid blood vessels connective deficiency permits plasma kallikrein activation leads production vasoactive peptide bradykinin also cleavage goes unchecked resulting autoactivation complement system common form presents marked swelling face mouth andor airway occurs spontaneously minimal triggers mild trauma swelling occur part body cases levels low protein circulates normal amounts dysfunctional addition episodes facial swelling andor abdominal pain also predisposes autoimmune diseases markedly lupus erythematosus due consumptive effect complement factors mutations gene codes may also play role development agerelated macular least diseasecausing mutations gene despite uncontrolled autoactivation important note levels key complement components low acute attack consumed indeed low levels key diagnostic test hereditary angioedema situation analogous low levels clotting factors found disseminated intravascular coagulation dic bloodderived effective carry risk associated use human blood product cinryze pharmaceuticalgrade approved use hae us available europe highly purified pasteurized nanofiltered plasmaderived esterase inhibitor product approved routine prophylaxis angioedema attacks adolescent adult patients recombinant obtained milk transgenic rabbits conestat alfa trade name ruconest approved treatment acute hae attacks therapy used acutely years europe patients deficiency new methods treating acute attacks emerged plasma kallikrein inhibitor bradykinin receptor antagonist icatibant products also introduced including plasmaderived products berinert activation complement cascade cause damage cells therefore inhibition complement cascade work medicine certain someone heart attack instance lack oxygen heart cells causes necrosis heart cells dying heart cells spill contents extracellular environment triggers complement cascade activation complement cascade attracts phagocytes leak peroxide reagents may increase damage surviving heart cells inhibition complement cascade decrease damage contained human blood therefore isolated donated blood risks infectious disease transmission viruses prions etc relative expense isolation prevented widespread use also possible produce recombinant technology escherichia coli commonly used organism purpose lacks eukaryotic ability glycosylate proteins particularly heavily glycosylated sialylated recombinant form would short circulatory life carbohydrates relevant inhibitor function therefore also produced glycosylated form using transgenic form recombinant also given orphan drug status delayed graft function following organ transplantation capillary leakage crystal structure latent human